Клиническая значимость достижения МОБ-негативности у больных хроническим лимфолейкозом
- Авторы: Миролюбова Ю.В.1, Стадник Е.А.2,1
-
Учреждения:
- ФГБУ «НМИЦ им. В.А.Алмазова»
- ФГБОУ ВО «Первый СПбГМУ им. И.П.Павлова»
- Выпуск: Том 20, № 1 (2018)
- Страницы: 17-22
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/27158
- ID: 27158
Цитировать
Полный текст
Аннотация
Определение минимальной остаточной болезни (МОБ) при хроническом лимфолейкозе (ХЛЛ) обрело значимость в связи с успехами терапии этого заболевания. Иммуннохимиотерапевтические схемы лечения продлили жизнь больных ХЛЛ, что ассоциировалось с достижением МОБ-негативных ремиссий. МОБ-статус стал расцениваться как предиктор беспрогрессивной выживаемости и конечная точка в клинических исследованиях. Применение новых препаратов - таргетных ингибиторов BCR-сигналинга, ингибиторов Bcl-2, новых моноклональных антител и их комбинаций - открыло перспективы для прогностически неблагоприятных вариантов ХЛЛ. Значение МОБ-негативности в эпоху новых препаратов стало объектом современных исследований. Развивались и методы определения МОБ при ХЛЛ. В статье представлены данные по влиянию МОБ-негативности на выживаемость пациентов на современном уровне развития терапии, а также перспективы клинического применения МОБ-статуса в практике ведения больных. В работе использованы результаты анализа МОБ в рамках проспективного исследования BEN-001, проведенного в России (бендамустин-ритуксимаб в 1-й линии терапии ХЛЛ). Проанализированы результаты определения МОБ-статуса методом проточной цитометрии у 84 человек. Образцы костного мозга были исследованы у 81 (96,4%) пациентов. МОБ-негативность после 6-го курса терапии составила 27,4%, что согласуется с данными, представленными в мировой литературе.
Полный текст
Открыть статью на сайте журналаОб авторах
Юлия Владимировна Миролюбова
ФГБУ «НМИЦ им. В.А.Алмазова»
Email: juli9702@yandex.ru
врач клинической лабораторной диагностики, ассистент каф. лабораторной диагностики и генетики 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2
Елена Александровна Стадник
ФГБОУ ВО «Первый СПбГМУ им. И.П.Павлова»; ФГБУ «НМИЦ им. В.А.Алмазова»
Email: elena_stadnik@mail.ru
канд. мед. наук; доц., ст. науч. сотр. 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2
Список литературы
- Swerdlow S.H, Campo E, Harris N.L et al. WHO classification of tumors of hematopoietic and lymphoid tissues. IARC, Lyon, 2008
- Swerdlow S.H, Campo E, Pileri S.A et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20): 2375-90. doi: 10.1182/blood-2016-01-643569
- Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. М., 2016; с. 224-53
- Hallek M, Cheson B.D, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111 (12): 5446-56.
- NCCN - Cinical Practice Guidelines in Oncology, B-cell lymphomas version 7.2017, https://www.nccn.org/professionals/physician_ gls/pdf/b-cell.pdf (accessed 29 Dec 2017)
- Keating M.J, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23 (18): 4079-88.
- Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23 (13): 2971-9.
- Rawstron A.C, Kennedy B, Evans P.A et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98 (1): 29-35.
- Vuillier F, Claisse J.F, Vandenvelde C et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7 (3): 195-204.
- Lenormand B, Bizet M, Fruchart C et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 1994; 8 (6): 1019-26.
- Cabezudo E, Matutes E, Ramrattan M et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997; 11: 1909-14.
- Rawstron A.C, Villamor N, Ritgen M et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21 (5): 956-64.
- Rawstron A.C, Bottcher S, Letestu R et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27 (1): 142-9.
- Rawstron A.C, Fazi C, Agathangelidis A et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016; 30 (4): 929-36.
- Farren T.W, Liu F, Macey M.G et al. Combined ROR1 and CD160 Detection for Improved Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2013; 122 (21): 2572.
- Farren T.W, Giustiniani J, Fanous M et al. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J 2015; 5 (1): e273.
- Voena C, Ladetto M, Astolfi M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11 (10): 1793-8.
- Böttcher S, Stilgenbauer S, Busch R et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009; 23 (11): 2007-17.
- Pfitzner T, Engert A, Wittor H et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia 2000; 14: 754-66.
- Logan A.C, Zhang B, Narasimhan B et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013; 27 (8): 1659-65.
- Thompson P.A, Wierda W.G. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood 2016; 127 (3): 279-86.
- Turtle C.J, Hay K.A, Hanafi L.A et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 2017; 35 (26): 3010-20.
- Stehlikova O, Chovancova J, Tichy B et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol 2014; 36 (2): 165-71.
- Луговская С.А., Почтарь М.Е., Наумова Е.В. Диагностика минимальной остаточной болезни при В-клеточном хроническом лимфолейкозе методом многопараметрической лазерной проточной цитофлюориметрии. Клин. лаб. диагностика. 2010; 9: 20-20а.
- Kovacs G, Robrecht S, Fink AM et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients with Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J Clin Oncol 2016; 34 (31): 3758-65.
- Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies EMA/629967/2014 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/12/WC500179047.pdf
- Böttcher S, Ritgen M, Fischer K et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30 (9): 980-8.
- Eichhorst B, Fink A.M, Bahlo J et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17 (7): 928-42.
- Kwok M, Rawstron A, Varghese A et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood 2016;
- (24): 2770-3.
- Thompson P.A, Tam C.S, O’Brien S.M. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127 (3): 303-9.
- Strati P, Keating M.J, O’Brien S.M et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014; 123 (24): 3727-32.
- Santacruz R, Villamor N, Aymerich M et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica 2014; 99 (5): 873-80.
- Herman S.E, Niemann C.U, Farooqui M et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28 (11): 2188-96.
- Chanan-Khan A, Cramer P, Demirkan F et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17 (2): 200-11.
- Collett L, Howard D.R, Munir T et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials 2017; 18 (1): 387.
- Sharman J.P, Farber C.M, Mahadevan D et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol 2017; 176 (3): 412-20.
- Winqvist M, Palma M, Heimersson K et al. Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study. Br J Haematol 2017. doi: 10.1111/bjh.14836 [Epub ahead of print]
- Hillmen P, Rawstron A, Munir T et al. The initial report of the Bloodwise TAP CLARITY study containing ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy. EHA 2017; Abstract S770
- Seymour J.F, Ma S, Brander D.M et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017; 18 (2): 230-40.
- Stilgenbauer S, Chyla B, Eichhorst B et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. EHA2017; Abstract S771.
- Stilgenbauer S, Morschhauser F, Wendtner C.M et al. Phase Ib study (GO28440) of Venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood 2016;
- (22): Abstract 4393.
- Varghese A.M, Howard D.R, Pocock C et al. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol 2017; 176 (4): 573-82.
- Oughton J.B, Collett L, Howard D.R.et al. GA101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials 2017; 18 (1): 353.
- Dreger P, Schetelig J, Andersen N et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124 (26): 3841-9.
- Dreger P, Dohner H, Ritgen M et al; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;
- (14): 2438-47.
- Farina L, Carniti C, Dodero A et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009; 94 (5): 654-62.
- Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 2017; 92 (9): 946-65.
- Никитин Е.А. Дифференцированная терапия хронического лимфолейкоза. Дис. … д-ра мед. наук. М., 2014.
- Кувшинов А.Ю., Волошин С.В., Мартынкевич И.С. и др. Хронический лимфолейкоз: прогностическое значение минимальной остаточной болезни, возможности современных методов ее выявления и коррекции (обзор литературы). Клин. онкогематология. 2016; 9 (2): 191-8.